Translational research in relation to cancer is a focus of our research. The strategic CREATE Health research centre, co-ordinated by the department, is therefore a focal point of our research. This vision of this strategic centre is to use an integrative approach to develop novel diagnostics and therapeutics in relation to cancer. We do this mainly by identifying markers and molecular signatures that differentiate cancer from other conditions. That way we intend to create a substantial social impact for the patient, through direct application of research for selection of an optimal, individually created, cancer treatment.
CanFaster, a MRSC CO-funded EU PhD program, running from 2018-2022 is directed from the Department of Immunotechnology and CREATE Health. The programme aims to attract excellent international PhD candidates with an interest in applied medical research in oncology and entrepreneurship to Lund University, CREATE health and Medicon Village. The program build on collaboration between industry, healthcare and academia to strengthen and accelerate innovations and clinical implementation in oncology. The PhD students will gain an understanding of unmet needs in the clinic and learn the mind-set of entrepreneurs in an upcoming PhD programme within cancer.
The department also operates two core facility units within SCIBLU, the Swegene Center for Integrative Biology at Lund University. These units offer researchers access to Affymetrix gene array platform and bioinformatics support in relation to such analysis. We also operate U-READ (Unit for Rapid Engineered Antibody Development) through which antibodies are developed using molecular engineering technology.